Edit
Kuros Biosurgery AG
http://www.kuros.ch/Last activity: 14.08.2025
Active - Reference to Kuros Biosciences
Kuros Biosurgery AG is a biotechnology company dedicated to developing biologics and biomaterials for local therapy within the core areas of trauma, wound and spine.
The company’s products are based on a technology platform that allows the combination of natural and synthetic matrices to active molecules and ensures its controlled release thereof.
Kuros Biosurgery AG has several products in clinical stages and its lead product KUR-111 met its primary efficacy endpoint in a Phase IIb study for tibial plateau fractures.
The company’s products are based on a technology platform that allows the combination of natural and synthetic matrices to active molecules and ensures its controlled release thereof.
Kuros Biosurgery AG has several products in clinical stages and its lead product KUR-111 met its primary efficacy endpoint in a Phase IIb study for tibial plateau fractures.
Location: Switzerland
Total raised: $81.8M
Investors 1
| Date | Name | Website |
| - | NeoMed Man... | neomed.net... |
Funding Rounds 7
| Date | Series | Amount | Investors |
| 05.12.2019 | - | $12.66M | - |
| 03.08.2017 | - | $17.56M | - |
| 11.11.2015 | - | $19.82M | - |
| 18.08.2015 | - | $15.5M | - |
| 06.10.2005 | - | $4.39M | - |
| 06.06.2004 | - | $4.9M | - |
| 06.11.2002 | - | $6.97M | - |
Mentions in press and media 14
| Date | Title | Description |
| 14.08.2025 | Kuros achieves first ever operating profit in H1 | The total group revenue reached USD 63.5 million, marking a growth of 78% compared to H1 2024. The company achieved an operating profit of USD 3.5 million in the first half of 2025, marking its first positive operating result, up from an o... |
| 05.12.2019 | Kuros raises CHF12.5 million | |
| 03.08.2017 | Kuros raises CHF 17M | |
| 22.04.2016 | Kuros receives milestone payment from Checkmate | |
| 21.01.2016 | Kuros on the stock exchange | |
| 03.12.2015 | Kuros and Cytos merge | |
| 16.11.2015 | KUROS announces second closing of a CHF 20 million financing round | |
| 11.11.2015 | Kuros Biosurgery Raises Additional CHF5M in Second Close of Financing | Kuros Biosurgery AG, a Zurich, Switzerland-based biotechnology company, raised an additional CHF5m in a second closing of its financing round. The total funding raised in the round now amounts to CHF20m. The first close of the financing ann... |
| 19.08.2015 | Kuros announces closing of a CHF 15m financing round | |
| 18.08.2015 | Kuros Biosurgery Closes CHF15M Financing | Kuros Biosurgery AG, a Zurich, Switzerland-based biotechnology company developing novel biomaterials and bioactive-biomaterial combination products and focused in therapeutic areas covering sealants and orthobiologics, closed a CHF15M finan... |
Show more